CARB-X Funds the 3rd Round of Debiopharm’s Targeted Antibiotic Program to Combat Resistant N. gonorrhoeae Infections
Debiopharm (www.debiopharm.com), a Swiss-based global biopharmaceutical company announced today having been awarded the third phase funding to advance the development of its antibiotic program, Debio 1453, by the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), a Boston-based non-profit accelerating antibacterial research. This extended financing will support the ongoing development of a novel antibiotic for the…
